Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company Advaxis. Based in Delaware, Ayala Pharmaceuticals is engaged in developing small molecule therapeutics for aggressive cancers and rare tumors. On the other hand, Advaxis is focused on developing immunotherapies based on a technology that makes use of […]
Ayala Pharmaceuticals has been granted fast track designation for its oral gamma-secretase inhibitor AL102 by the US Food and Drug Administration (FDA) for the treatment of progressing desmoid tumors. AL102 is currently being assessed by the clinical-stage oncology company in the phase 2/3 RINGSIDE clinical trial in desmoid tumors. According to Ayala Pharmaceuticals, in Part […]
